Summary

The global Investigational New Drug CDMO market is projected to grow from US$ 19850 million in 2025 to US$ 36455 million by 2032, at a CAGR of 9.1% (2026-2032), driven by critical product segments and diverse end‑use applications.
Investigational New Drug CDMO services comprise outsourced CMC development and GMP manufacturing that convert a preclinical drug candidate into clinical-trial-ready drug substance and drug product and then supply Phase I–III studies. The scope includes process, formulation and analytical development, method validation, stability, IND/IMPD-supporting documentation, GMP clinical batches, aseptic or oral drug-product manufacture, packaging and integrated clinical supply when connected to development/manufacturing. It covers small molecules, biologics, peptides, oligonucleotides, ADCs and advanced therapies.
Key Findings
Integrated pre-IND-to-clinic platforms reduce technology transfers
Emerging biotech demand favors flexible small-batch capacity
Complex modalities raise analytical and aseptic manufacturing value
Market Trends
Sponsors increasingly select CDMOs before IND-enabling studies so process, analytical, formulation and manufacturing decisions are made with later clinical scale in mind. Platform development, standardized cell-line or chemistry packages and integrated drug-substance/drug-product execution shorten handoffs. Demand is also moving toward high-potency, sterile, biologic and advanced-therapy capabilities, where analytical characterization, regulatory documentation and supply-chain resilience determine timelines more than nominal reactor capacity.
Market Dynamics
Drivers
A growing biotech pipeline, constrained internal CMC teams and pressure to reach first-in-human dosing accelerate outsourcing. Complex modalities and global trials increase demand for specialized GMP facilities and integrated supply.
Restraints
Funding cycles can delay or cancel early programs, while technology transfer, minimum campaign size and scarce specialist capacity increase switching costs. Sponsors may retain strategic processes internally.
Opportunities
DNA-to-IND, candidate-to-clinic and one-site drug-substance/drug-product offerings can compress timelines. Flexible suites, continuous manufacturing, high-potency containment, prefilled syringes and regional dual sourcing create differentiated growth.
Challenges
CDMOs must manage immature processes, changing forecasts and phase-appropriate controls without compromising data integrity. Regulatory observations, contamination, batch failure or late analytical gaps can stop a trial and damage multi-client capacity schedules.
Industry Chain Analysis
Upstream resources include starting materials, excipients, single-use bioprocess components, cell lines, plasmids, media, chromatography resins, vials, stoppers, analytical instruments and cold-chain inputs. CDMOs integrate developability assessment, process and formulation design, analytical methods, scale-up, GMP drug-substance and drug-product batches, release, stability and regulatory CMC packages. Clinical supply teams add packaging, randomization labels, storage and distribution, while sponsors and clinical sites administer the investigational product. Value concentrates in scientific problem solving, validated quality systems, regulatory-ready data, flexible GMP capacity and on-time clinical release; simple material procurement carries lower margin.
Segment Insights
Small molecules remain the largest modality by project count and benefit from broad chemistry, API and oral-dose infrastructure. Monoclonal antibodies and recombinant proteins command larger campaign values and increasingly use standardized cell-line-to-IND platforms. Peptides, oligonucleotides and ADCs require specialized synthesis, conjugation and high-containment analytics. Cell and gene therapies have smaller project counts but high service intensity because vector production, potency assays, aseptic handling and chain-of-identity controls are complex.
Downstream Market Opportunities
Pre-IND and Phase I programs offer the largest customer-acquisition opportunity because emerging biotech sponsors need rapid process definition, tox and GMP material, regulatory CMC support and first clinical supply. Phase II creates repeat campaigns, formulation optimization and scale-up work. Phase III and registration-enabling programs deliver larger revenue but demand validated processes, redundancy and inspection readiness. Integrated providers can retain programs across stages; specialists win where potency, modality or dosage-form complexity outweighs one-stop convenience.
Regional Insights
North America is the largest source of emerging-biotech projects and a major center for sterile, biologic and advanced-therapy outsourcing. Europe combines mature API, biologics and fill-finish clusters with strict IMPD and Qualified Person release practices. China has developed a broad preclinical-to-clinical CDMO base led by companies including WuXi AppTec, STA Pharmaceutical, Asymchem Laboratories (Tianjin) Co., Ltd., Porton Pharma Solutions Ltd., Pharmaron Beijing Co., Ltd., Zhejiang Jiuzhou Pharmaceutical Co., Ltd., MabPlex International, DINGKANG BIO and GenScript ProBio. Japan and South Korea are expanding biologics capacity, while sponsors increasingly qualify regional backups to manage geopolitical and logistics risk.
Competitive Landscape Analysis
Verified representative providers include Thermo Fisher Scientific Patheon, Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Boehringer Ingelheim BioXcellence, Rentschler Biopharma, Siegfried, Cambrex, CordenPharma, Curia, Piramal Pharma Solutions, Recipharm, PCI Pharma Services, Almac Group, Ajinomoto Bio-Pharma Services, Vetter, WuXi AppTec, STA Pharmaceutical, Asymchem Laboratories (Tianjin) Co., Ltd., Porton Pharma Solutions Ltd., Pharmaron Beijing Co., Ltd., Zhejiang Jiuzhou Pharmaceutical Co., Ltd., MabPlex International, DINGKANG BIO and GenScript ProBio. Global scale players compete on integrated modality breadth and network capacity; specialists compete on speed, scientific depth and flexible batches. Inclusion reflects official service evidence, not an audited revenue ranking.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Investigational New Drug CDMO market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by End User, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Thermo Fisher Scientific Patheon
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
AGC Biologics
Boehringer Ingelheim BioXcellence
Rentschler Biopharma
Siegfried
Cambrex
CordenPharma
Curia
Piramal Pharma Solutions
Recipharm
PCI Pharma Services
Almac Group
Ajinomoto Bio-Pharma Services
Vetter
WuXi AppTec
STA Pharmaceutical
Asymchem Laboratories (Tianjin) Co., Ltd.
Porton Pharma Solutions Ltd.
Pharmaron Beijing Co., Ltd.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
MabPlex International
DINGKANG BIO
GenScript ProBio
Segment by Type
Small Molecules
Monoclonal Antibodies and Recombinant Proteins
Peptides and Oligonucleotides
Cell and Gene Therapies
ADCs and Other Complex Modalities
Segment by Clinical Phase
Pre-IND and Phase I
Phase II
Phase III and Registration-enabling
Segment by Service Stage
Preformulation and CMC Development
Process and Analytical Development
GMP Clinical Drug-substance Manufacturing
Clinical Drug-product Manufacturing
Packaging, Labeling and Clinical Supply
Segment by End User
Biotech Companies
Pharma Companies
Academic and Virtual Biotech
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Investigational New Drug CDMO study scope, segments the market by Type and by End User, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by End User, identifies emerging use cases, and profiles leading customers by region and by End User
Chapter 6: North America: breaks down market size by End User and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by End User and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by End User, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by End User, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by End User, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by End User, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Investigational New Drug CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Investigational New Drug CDMO Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Small Molecules
1.2.3 Monoclonal Antibodies and Recombinant Proteins
1.2.4 Peptides and Oligonucleotides
1.2.5 Cell and Gene Therapies
1.2.6 ADCs and Other Complex Modalities
1.3 Market Segmentation by Clinical Phase
1.3.1 Global Investigational New Drug CDMO Market Size by Clinical Phase, 2021 vs 2025 vs 2032
1.3.2 Pre-IND and Phase I
1.3.3 Phase II
1.3.4 Phase III and Registration-enabling
1.4 Market Segmentation by Service Stage
1.4.1 Global Investigational New Drug CDMO Market Size by Service Stage, 2021 vs 2025 vs 2032
1.4.2 Preformulation and CMC Development
1.4.3 Process and Analytical Development
1.4.4 GMP Clinical Drug-substance Manufacturing
1.4.5 Clinical Drug-product Manufacturing
1.4.6 Packaging, Labeling and Clinical Supply
1.5 Market Segmentation by End User
1.5.1 Global Investigational New Drug CDMO Market Size by End User, 2021 vs 2025 vs 2032
1.5.2 Biotech Companies
1.5.3 Pharma Companies
1.5.4 Academic and Virtual Biotech
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Investigational New Drug CDMO Revenue Estimates and Forecasts (2021-2032)
2.2 Global Investigational New Drug CDMO Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Investigational New Drug CDMO Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Investigational New Drug CDMO Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Small Molecules: Market Share by Key Players
3.3.2 Monoclonal Antibodies and Recombinant Proteins: Market Share by Key Players
3.3.3 Peptides and Oligonucleotides: Market Share by Key Players
3.3.4 Cell and Gene Therapies: Market Share by Key Players
3.3.5 ADCs and Other Complex Modalities: Market Share by Key Players
3.4 Global Investigational New Drug CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Investigational New Drug CDMO Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Investigational New Drug CDMO Market by Clinical Phase
4.2.1 Global Revenue by Clinical Phase (2021-2032)
4.2.2 Global Revenue-Based Market Share by Clinical Phase (2021-2032)
4.3 Global Investigational New Drug CDMO Market by Service Stage
4.3.1 Global Revenue by Service Stage (2021-2032)
4.3.2 Global Revenue-Based Market Share by Service Stage (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Investigational New Drug CDMO Revenue by End User
5.1.1 Global Historical and Forecasted Revenue by End User (2021-2032)
5.1.2 Revenue-Based Market Share by End User (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by End User

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Investigational New Drug CDMO Market Size by End User (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Investigational New Drug CDMO Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Investigational New Drug CDMO Market Size by End User (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Investigational New Drug CDMO Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Investigational New Drug CDMO Market Size by End User (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Investigational New Drug CDMO Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Investigational New Drug CDMO Market Size by End User (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Investigational New Drug CDMO Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Investigational New Drug CDMO Market Size by End User (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Investigational New Drug CDMO Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Thermo Fisher Scientific Patheon
11.1.1 Thermo Fisher Scientific Patheon Corporation Information
11.1.2 Thermo Fisher Scientific Patheon Business Overview
11.1.3 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Product Features and Attributes
11.1.4 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.1.5 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Revenue by Product in 2025
11.1.6 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Revenue by End User in 2025
11.1.7 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Revenue by Geographic Area in 2025
11.1.8 Thermo Fisher Scientific Patheon Investigational New Drug CDMO SWOT Analysis
11.1.9 Thermo Fisher Scientific Patheon Recent Developments
11.2 Lonza
11.2.1 Lonza Corporation Information
11.2.2 Lonza Business Overview
11.2.3 Lonza Investigational New Drug CDMO Product Features and Attributes
11.2.4 Lonza Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.2.5 Lonza Investigational New Drug CDMO Revenue by Product in 2025
11.2.6 Lonza Investigational New Drug CDMO Revenue by End User in 2025
11.2.7 Lonza Investigational New Drug CDMO Revenue by Geographic Area in 2025
11.2.8 Lonza Investigational New Drug CDMO SWOT Analysis
11.2.9 Lonza Recent Developments
11.3 Catalent
11.3.1 Catalent Corporation Information
11.3.2 Catalent Business Overview
11.3.3 Catalent Investigational New Drug CDMO Product Features and Attributes
11.3.4 Catalent Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.3.5 Catalent Investigational New Drug CDMO Revenue by Product in 2025
11.3.6 Catalent Investigational New Drug CDMO Revenue by End User in 2025
11.3.7 Catalent Investigational New Drug CDMO Revenue by Geographic Area in 2025
11.3.8 Catalent Investigational New Drug CDMO SWOT Analysis
11.3.9 Catalent Recent Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Corporation Information
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Investigational New Drug CDMO Product Features and Attributes
11.4.4 Samsung Biologics Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.4.5 Samsung Biologics Investigational New Drug CDMO Revenue by Product in 2025
11.4.6 Samsung Biologics Investigational New Drug CDMO Revenue by End User in 2025
11.4.7 Samsung Biologics Investigational New Drug CDMO Revenue by Geographic Area in 2025
11.4.8 Samsung Biologics Investigational New Drug CDMO SWOT Analysis
11.4.9 Samsung Biologics Recent Developments
11.5 FUJIFILM Diosynth Biotechnologies
11.5.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.5.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.5.3 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Product Features and Attributes
11.5.4 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.5.5 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Revenue by Product in 2025
11.5.6 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Revenue by End User in 2025
11.5.7 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Revenue by Geographic Area in 2025
11.5.8 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO SWOT Analysis
11.5.9 FUJIFILM Diosynth Biotechnologies Recent Developments
11.6 AGC Biologics
11.6.1 AGC Biologics Corporation Information
11.6.2 AGC Biologics Business Overview
11.6.3 AGC Biologics Investigational New Drug CDMO Product Features and Attributes
11.6.4 AGC Biologics Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.6.5 AGC Biologics Recent Developments
11.7 Boehringer Ingelheim BioXcellence
11.7.1 Boehringer Ingelheim BioXcellence Corporation Information
11.7.2 Boehringer Ingelheim BioXcellence Business Overview
11.7.3 Boehringer Ingelheim BioXcellence Investigational New Drug CDMO Product Features and Attributes
11.7.4 Boehringer Ingelheim BioXcellence Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.7.5 Boehringer Ingelheim BioXcellence Recent Developments
11.8 Rentschler Biopharma
11.8.1 Rentschler Biopharma Corporation Information
11.8.2 Rentschler Biopharma Business Overview
11.8.3 Rentschler Biopharma Investigational New Drug CDMO Product Features and Attributes
11.8.4 Rentschler Biopharma Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.8.5 Rentschler Biopharma Recent Developments
11.9 Siegfried
11.9.1 Siegfried Corporation Information
11.9.2 Siegfried Business Overview
11.9.3 Siegfried Investigational New Drug CDMO Product Features and Attributes
11.9.4 Siegfried Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.9.5 Siegfried Recent Developments
11.10 Cambrex
11.10.1 Cambrex Corporation Information
11.10.2 Cambrex Business Overview
11.10.3 Cambrex Investigational New Drug CDMO Product Features and Attributes
11.10.4 Cambrex Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 CordenPharma
11.11.1 CordenPharma Corporation Information
11.11.2 CordenPharma Business Overview
11.11.3 CordenPharma Investigational New Drug CDMO Product Features and Attributes
11.11.4 CordenPharma Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.11.5 CordenPharma Recent Developments
11.12 Curia
11.12.1 Curia Corporation Information
11.12.2 Curia Business Overview
11.12.3 Curia Investigational New Drug CDMO Product Features and Attributes
11.12.4 Curia Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.12.5 Curia Recent Developments
11.13 Piramal Pharma Solutions
11.13.1 Piramal Pharma Solutions Corporation Information
11.13.2 Piramal Pharma Solutions Business Overview
11.13.3 Piramal Pharma Solutions Investigational New Drug CDMO Product Features and Attributes
11.13.4 Piramal Pharma Solutions Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.13.5 Piramal Pharma Solutions Recent Developments
11.14 Recipharm
11.14.1 Recipharm Corporation Information
11.14.2 Recipharm Business Overview
11.14.3 Recipharm Investigational New Drug CDMO Product Features and Attributes
11.14.4 Recipharm Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.14.5 Recipharm Recent Developments
11.15 PCI Pharma Services
11.15.1 PCI Pharma Services Corporation Information
11.15.2 PCI Pharma Services Business Overview
11.15.3 PCI Pharma Services Investigational New Drug CDMO Product Features and Attributes
11.15.4 PCI Pharma Services Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.15.5 PCI Pharma Services Recent Developments
11.16 Almac Group
11.16.1 Almac Group Corporation Information
11.16.2 Almac Group Business Overview
11.16.3 Almac Group Investigational New Drug CDMO Product Features and Attributes
11.16.4 Almac Group Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.16.5 Almac Group Recent Developments
11.17 Ajinomoto Bio-Pharma Services
11.17.1 Ajinomoto Bio-Pharma Services Corporation Information
11.17.2 Ajinomoto Bio-Pharma Services Business Overview
11.17.3 Ajinomoto Bio-Pharma Services Investigational New Drug CDMO Product Features and Attributes
11.17.4 Ajinomoto Bio-Pharma Services Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.17.5 Ajinomoto Bio-Pharma Services Recent Developments
11.18 Vetter
11.18.1 Vetter Corporation Information
11.18.2 Vetter Business Overview
11.18.3 Vetter Investigational New Drug CDMO Product Features and Attributes
11.18.4 Vetter Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.18.5 Vetter Recent Developments
11.19 WuXi AppTec
11.19.1 WuXi AppTec Corporation Information
11.19.2 WuXi AppTec Business Overview
11.19.3 WuXi AppTec Investigational New Drug CDMO Product Features and Attributes
11.19.4 WuXi AppTec Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.19.5 WuXi AppTec Recent Developments
11.20 STA Pharmaceutical
11.20.1 STA Pharmaceutical Corporation Information
11.20.2 STA Pharmaceutical Business Overview
11.20.3 STA Pharmaceutical Investigational New Drug CDMO Product Features and Attributes
11.20.4 STA Pharmaceutical Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.20.5 STA Pharmaceutical Recent Developments
11.21 Asymchem Laboratories (Tianjin) Co., Ltd.
11.21.1 Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
11.21.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview
11.21.3 Asymchem Laboratories (Tianjin) Co., Ltd. Investigational New Drug CDMO Product Features and Attributes
11.21.4 Asymchem Laboratories (Tianjin) Co., Ltd. Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.21.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
11.22 Porton Pharma Solutions Ltd.
11.22.1 Porton Pharma Solutions Ltd. Corporation Information
11.22.2 Porton Pharma Solutions Ltd. Business Overview
11.22.3 Porton Pharma Solutions Ltd. Investigational New Drug CDMO Product Features and Attributes
11.22.4 Porton Pharma Solutions Ltd. Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.22.5 Porton Pharma Solutions Ltd. Recent Developments
11.23 Pharmaron Beijing Co., Ltd.
11.23.1 Pharmaron Beijing Co., Ltd. Corporation Information
11.23.2 Pharmaron Beijing Co., Ltd. Business Overview
11.23.3 Pharmaron Beijing Co., Ltd. Investigational New Drug CDMO Product Features and Attributes
11.23.4 Pharmaron Beijing Co., Ltd. Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.23.5 Pharmaron Beijing Co., Ltd. Recent Developments
11.24 Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
11.24.1 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Corporation Information
11.24.2 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Business Overview
11.24.3 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Investigational New Drug CDMO Product Features and Attributes
11.24.4 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.24.5 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Recent Developments
11.25 MabPlex International
11.25.1 MabPlex International Corporation Information
11.25.2 MabPlex International Business Overview
11.25.3 MabPlex International Investigational New Drug CDMO Product Features and Attributes
11.25.4 MabPlex International Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.25.5 MabPlex International Recent Developments
11.26 DINGKANG BIO
11.26.1 DINGKANG BIO Corporation Information
11.26.2 DINGKANG BIO Business Overview
11.26.3 DINGKANG BIO Investigational New Drug CDMO Product Features and Attributes
11.26.4 DINGKANG BIO Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.26.5 DINGKANG BIO Recent Developments
11.27 GenScript ProBio
11.27.1 GenScript ProBio Corporation Information
11.27.2 GenScript ProBio Business Overview
11.27.3 GenScript ProBio Investigational New Drug CDMO Product Features and Attributes
11.27.4 GenScript ProBio Investigational New Drug CDMO Revenue and Gross Margin (2021-2026)
11.27.5 GenScript ProBio Recent Developments

12 Investigational New Drug CDMO Value Chain and Ecosystem Analysis
12.1 Investigational New Drug CDMO Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Investigational New Drug CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Investigational New Drug CDMO Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Investigational New Drug CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Investigational New Drug CDMO Market Size Growth Rate by Clinical Phase, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Investigational New Drug CDMO Market Size Growth Rate by Service Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Investigational New Drug CDMO Market Size Growth Rate by End User, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Investigational New Drug CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Investigational New Drug CDMO Revenue by Region (US$ Million), 2021-2026
Table 7. Global Investigational New Drug CDMO Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Investigational New Drug CDMO Revenue by Players (US$ Million), 2021-2026
Table 10. Global Investigational New Drug CDMO Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Investigational New Drug CDMO Revenue, 2025
Table 13. Global Investigational New Drug CDMO Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Investigational New Drug CDMO Companies Headquarters
Table 15. Global Investigational New Drug CDMO Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Investigational New Drug CDMO Revenue by Type (US$ Million), 2021-2026
Table 19. Global Investigational New Drug CDMO Revenue by Type (US$ Million), 2027-2032
Table 20. Global Investigational New Drug CDMO Revenue by Clinical Phase (US$ Million), 2021-2026
Table 21. Global Investigational New Drug CDMO Revenue by Clinical Phase (US$ Million), 2027-2032
Table 22. Global Investigational New Drug CDMO Revenue by Service Stage (US$ Million), 2021-2026
Table 23. Global Investigational New Drug CDMO Revenue by Service Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Investigational New Drug CDMO Revenue by End User (US$ Million), 2021-2026
Table 26. Global Investigational New Drug CDMO Revenue by End User (US$ Million), 2027-2032
Table 27. Investigational New Drug CDMO High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by End User
Table 30. North America Investigational New Drug CDMO Growth Accelerators and Market Barriers
Table 31. North America Investigational New Drug CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Investigational New Drug CDMO Growth Accelerators and Market Barriers
Table 33. Europe Investigational New Drug CDMO Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Investigational New Drug CDMO Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Investigational New Drug CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Investigational New Drug CDMO Investment Opportunities and Key Challenges
Table 37. Central and South America Investigational New Drug CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Investigational New Drug CDMO Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Investigational New Drug CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Thermo Fisher Scientific Patheon Corporation Information
Table 41. Thermo Fisher Scientific Patheon Description and Major Businesses
Table 42. Thermo Fisher Scientific Patheon Product Features and Attributes
Table 43. Thermo Fisher Scientific Patheon Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Thermo Fisher Scientific Patheon Revenue Proportion by Product in 2025
Table 45. Thermo Fisher Scientific Patheon Revenue Proportion by End User in 2025
Table 46. Thermo Fisher Scientific Patheon Revenue Proportion by Geographic Area in 2025
Table 47. Thermo Fisher Scientific Patheon Investigational New Drug CDMO SWOT Analysis
Table 48. Thermo Fisher Scientific Patheon Recent Developments
Table 49. Lonza Corporation Information
Table 50. Lonza Description and Major Businesses
Table 51. Lonza Product Features and Attributes
Table 52. Lonza Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Lonza Revenue Proportion by Product in 2025
Table 54. Lonza Revenue Proportion by End User in 2025
Table 55. Lonza Revenue Proportion by Geographic Area in 2025
Table 56. Lonza Investigational New Drug CDMO SWOT Analysis
Table 57. Lonza Recent Developments
Table 58. Catalent Corporation Information
Table 59. Catalent Description and Major Businesses
Table 60. Catalent Product Features and Attributes
Table 61. Catalent Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Catalent Revenue Proportion by Product in 2025
Table 63. Catalent Revenue Proportion by End User in 2025
Table 64. Catalent Revenue Proportion by Geographic Area in 2025
Table 65. Catalent Investigational New Drug CDMO SWOT Analysis
Table 66. Catalent Recent Developments
Table 67. Samsung Biologics Corporation Information
Table 68. Samsung Biologics Description and Major Businesses
Table 69. Samsung Biologics Product Features and Attributes
Table 70. Samsung Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Samsung Biologics Revenue Proportion by Product in 2025
Table 72. Samsung Biologics Revenue Proportion by End User in 2025
Table 73. Samsung Biologics Revenue Proportion by Geographic Area in 2025
Table 74. Samsung Biologics Investigational New Drug CDMO SWOT Analysis
Table 75. Samsung Biologics Recent Developments
Table 76. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 77. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 78. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 79. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Product in 2025
Table 81. FUJIFILM Diosynth Biotechnologies Revenue Proportion by End User in 2025
Table 82. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Geographic Area in 2025
Table 83. FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO SWOT Analysis
Table 84. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 85. AGC Biologics Corporation Information
Table 86. AGC Biologics Description and Major Businesses
Table 87. AGC Biologics Product Features and Attributes
Table 88. AGC Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. AGC Biologics Recent Developments
Table 90. Boehringer Ingelheim BioXcellence Corporation Information
Table 91. Boehringer Ingelheim BioXcellence Description and Major Businesses
Table 92. Boehringer Ingelheim BioXcellence Product Features and Attributes
Table 93. Boehringer Ingelheim BioXcellence Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Boehringer Ingelheim BioXcellence Recent Developments
Table 95. Rentschler Biopharma Corporation Information
Table 96. Rentschler Biopharma Description and Major Businesses
Table 97. Rentschler Biopharma Product Features and Attributes
Table 98. Rentschler Biopharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Rentschler Biopharma Recent Developments
Table 100. Siegfried Corporation Information
Table 101. Siegfried Description and Major Businesses
Table 102. Siegfried Product Features and Attributes
Table 103. Siegfried Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Siegfried Recent Developments
Table 105. Cambrex Corporation Information
Table 106. Cambrex Description and Major Businesses
Table 107. Cambrex Product Features and Attributes
Table 108. Cambrex Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Cambrex Recent Developments
Table 110. CordenPharma Corporation Information
Table 111. CordenPharma Description and Major Businesses
Table 112. CordenPharma Product Features and Attributes
Table 113. CordenPharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. CordenPharma Recent Developments
Table 115. Curia Corporation Information
Table 116. Curia Description and Major Businesses
Table 117. Curia Product Features and Attributes
Table 118. Curia Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Curia Recent Developments
Table 120. Piramal Pharma Solutions Corporation Information
Table 121. Piramal Pharma Solutions Description and Major Businesses
Table 122. Piramal Pharma Solutions Product Features and Attributes
Table 123. Piramal Pharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Piramal Pharma Solutions Recent Developments
Table 125. Recipharm Corporation Information
Table 126. Recipharm Description and Major Businesses
Table 127. Recipharm Product Features and Attributes
Table 128. Recipharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Recipharm Recent Developments
Table 130. PCI Pharma Services Corporation Information
Table 131. PCI Pharma Services Description and Major Businesses
Table 132. PCI Pharma Services Product Features and Attributes
Table 133. PCI Pharma Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. PCI Pharma Services Recent Developments
Table 135. Almac Group Corporation Information
Table 136. Almac Group Description and Major Businesses
Table 137. Almac Group Product Features and Attributes
Table 138. Almac Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Almac Group Recent Developments
Table 140. Ajinomoto Bio-Pharma Services Corporation Information
Table 141. Ajinomoto Bio-Pharma Services Description and Major Businesses
Table 142. Ajinomoto Bio-Pharma Services Product Features and Attributes
Table 143. Ajinomoto Bio-Pharma Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Ajinomoto Bio-Pharma Services Recent Developments
Table 145. Vetter Corporation Information
Table 146. Vetter Description and Major Businesses
Table 147. Vetter Product Features and Attributes
Table 148. Vetter Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Vetter Recent Developments
Table 150. WuXi AppTec Corporation Information
Table 151. WuXi AppTec Description and Major Businesses
Table 152. WuXi AppTec Product Features and Attributes
Table 153. WuXi AppTec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. WuXi AppTec Recent Developments
Table 155. STA Pharmaceutical Corporation Information
Table 156. STA Pharmaceutical Description and Major Businesses
Table 157. STA Pharmaceutical Product Features and Attributes
Table 158. STA Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. STA Pharmaceutical Recent Developments
Table 160. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 161. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 162. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 163. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 165. Porton Pharma Solutions Ltd. Corporation Information
Table 166. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 167. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 168. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Porton Pharma Solutions Ltd. Recent Developments
Table 170. Pharmaron Beijing Co., Ltd. Corporation Information
Table 171. Pharmaron Beijing Co., Ltd. Description and Major Businesses
Table 172. Pharmaron Beijing Co., Ltd. Product Features and Attributes
Table 173. Pharmaron Beijing Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Pharmaron Beijing Co., Ltd. Recent Developments
Table 175. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Corporation Information
Table 176. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Description and Major Businesses
Table 177. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Product Features and Attributes
Table 178. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Recent Developments
Table 180. MabPlex International Corporation Information
Table 181. MabPlex International Description and Major Businesses
Table 182. MabPlex International Product Features and Attributes
Table 183. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. MabPlex International Recent Developments
Table 185. DINGKANG BIO Corporation Information
Table 186. DINGKANG BIO Description and Major Businesses
Table 187. DINGKANG BIO Product Features and Attributes
Table 188. DINGKANG BIO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. DINGKANG BIO Recent Developments
Table 190. GenScript ProBio Corporation Information
Table 191. GenScript ProBio Description and Major Businesses
Table 192. GenScript ProBio Product Features and Attributes
Table 193. GenScript ProBio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. GenScript ProBio Recent Developments
Table 195. Technologies, Platforms and Infrastructure
Table 196. Distributors List
Table 197. Market Trends and Market Evolution
Table 198. Market Drivers and Opportunities
Table 199. Market Challenges, Risks, and Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Investigational New Drug CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Small Molecules Product Picture
Figure 3. Monoclonal Antibodies and Recombinant Proteins Product Picture
Figure 4. Peptides and Oligonucleotides Product Picture
Figure 5. Cell and Gene Therapies Product Picture
Figure 6. ADCs and Other Complex Modalities Product Picture
Figure 7. Global Investigational New Drug CDMO Market Size Growth Rate by Clinical Phase, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Pre-IND and Phase I Product Picture
Figure 9. Phase II Product Picture
Figure 10. Phase III and Registration-enabling Product Picture
Figure 11. Global Investigational New Drug CDMO Market Size Growth Rate by Service Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Preformulation and CMC Development Product Picture
Figure 13. Process and Analytical Development Product Picture
Figure 14. GMP Clinical Drug-substance Manufacturing Product Picture
Figure 15. Clinical Drug-product Manufacturing Product Picture
Figure 16. Packaging, Labeling and Clinical Supply Product Picture
Figure 17. Global Investigational New Drug CDMO Market Size Growth Rate by End User, 2021 vs 2025 vs 2032 (US$ Million)
Figure 18. Biotech Companies
Figure 19. Pharma Companies
Figure 20. Academic and Virtual Biotech
Figure 21. Investigational New Drug CDMO Report Years Considered
Figure 22. Global Investigational New Drug CDMO Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 24. Global Investigational New Drug CDMO Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 25. Global Investigational New Drug CDMO Revenue-Based Market Share by Region (2021-2032)
Figure 26. Global Investigational New Drug CDMO Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. Small Molecules Revenue-Based Market Share by Player in 2025
Figure 29. Monoclonal Antibodies and Recombinant Proteins Revenue-Based Market Share by Player in 2025
Figure 30. Peptides and Oligonucleotides Revenue-Based Market Share by Player in 2025
Figure 31. Cell and Gene Therapies Revenue-Based Market Share by Player in 2025
Figure 32. ADCs and Other Complex Modalities Revenue-Based Market Share by Player in 2025
Figure 33. Global Investigational New Drug CDMO Revenue-Based Market Share by Type (2021-2032)
Figure 34. Global Investigational New Drug CDMO Revenue-Based Market Share by Clinical Phase (2021-2032)
Figure 35. Global Investigational New Drug CDMO Revenue-Based Market Share by Service Stage (2021-2032)
Figure 36. Global Investigational New Drug CDMO Revenue-Based Market Share by End User (2021-2032)
Figure 37. North America Investigational New Drug CDMO Revenue YoY (US$ Million), 2021-2032
Figure 38. North America Top 5 Players Investigational New Drug CDMO Revenue (US$ Million) in 2025
Figure 39. North America Investigational New Drug CDMO Revenue (US$ Million) by End User (2021-2032)
Figure 40. US Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 41. Canada Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 42. Mexico Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 43. Europe Investigational New Drug CDMO Revenue YoY (US$ Million), 2021-2032
Figure 44. Europe Top 5 Players Investigational New Drug CDMO Revenue (US$ Million) in 2025
Figure 45. Europe Investigational New Drug CDMO Revenue (US$ Million) by End User (2021-2032)
Figure 46. Germany Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 47. France Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 48. U.K. Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 49. Italy Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 50. Russia Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 51. Asia-Pacific Investigational New Drug CDMO Revenue YoY (US$ Million), 2021-2032
Figure 52. Asia-Pacific Top 8 Players Investigational New Drug CDMO Revenue (US$ Million) in 2025
Figure 53. Asia-Pacific Investigational New Drug CDMO Revenue (US$ Million) by End User (2021-2032)
Figure 54. Indonesia Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 55. Japan Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 56. South Korea Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 57. Australia Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 58. India Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 59. Indonesia Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 60. Vietnam Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 61. Malaysia Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 62. Philippines Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 63. Singapore Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 64. Central and South America Investigational New Drug CDMO Revenue YoY (US$ Million), 2021-2032
Figure 65. Central and South America Top 5 Players Investigational New Drug CDMO Revenue (US$ Million) in 2025
Figure 66. Central and South America Investigational New Drug CDMO Revenue (US$ Million) by End User (2021-2032)
Figure 67. Brazil Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 68. Argentina Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 69. Middle East and Africa Investigational New Drug CDMO Revenue YoY (US$ Million), 2021-2032
Figure 70. Middle East and Africa Top 5 Players Investigational New Drug CDMO Revenue (US$ Million) in 2025
Figure 71. Middle East and Africa Investigational New Drug CDMO Revenue (US$ Million) by End User (2021-2032)
Figure 72. GCC Countries Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 73. Israel Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 74. Egypt Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 75. South Africa Investigational New Drug CDMO Revenue (US$ Million), 2021-2032
Figure 76. Investigational New Drug CDMO Value Chain Mapping
Figure 77. Channels of Distribution (Direct Vs Distribution)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed